par Dupont, Christophe;Soulaines, Pascale;Kalach, Nicolas;Bradatan, Elena;Lachaux, Alain;Payot, François;De Blay, Frédéric;Guénard-Bilbault, Lydie;Hatahet, Riad;Mulier, Sandra 
Référence Paediatric drugs, 16, 6, page (513-522)
Publication Publié, 2014-12
Référence Paediatric drugs, 16, 6, page (513-522)
Publication Publié, 2014-12
Article révisé par les pairs
| Résumé : | Results: Of the 86 infants randomized, CMPA with eHF intolerance was confirmed in 75 infants; all of them tolerated the allocated AAFs. The major allergic symptom disappeared within 1 month in 61.9 and 51.5 % and regurgitations disappeared in 66.7 and 42.3 % of infants who received TAAF and RAAF, respectively. Infants had significantly more normal stools (soft or formed consistency) with the TAAF (90.5 vs. 66.7 %; p = 0.011). From baseline, daily family life significantly improved with both AAFs: crying time decreased by 97.3 (p < 0.001) and 28.6 min (p = 0.014) and sleeping time increased by 64.6 (p = 0.009) and 29.0 min with TAAF and RAAF, respectively. At day 30, weight and body mass index z-score gains were 0.1 and 0.2 with TAAF and 0.2 and 0.0 with RAAF. |
